Ai In Cell And Gene Therapy Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The AI in Cell and Gene Therapy market encompasses AI and machine learning tools deployed across the entire advanced therapy lifecycle, from target identification and vector design to manufacturing scale-up and clinical trial optimization. With a 2026 valuation of $18.6 billion, the market sits within a broader cell and gene therapy industry projected at $22.30 billion to $25.20 billion in 2025, demonstrating that AI applications already represent a substantial share of total sector value. The market's projected expansion to $122.86 billion by 2031 underscores the deepening reliance on intelligent automation and data-driven workflows as therapies move from niche treatments toward mainstream therapeutics.

Manufacturing bottlenecks and the high cost of cell and gene therapy production remain the primary catalysts for AI adoption, with machine learning and robotic automation offering solutions for process optimization and yield improvement. Pharmaceutical companies have deployed multi-billion dollar investments in biopharma AI, recognizing that intelligent systems can compress development timelines and improve reproducibility in cell and gene therapy manufacturing. Additional drivers include regulatory pressure to improve therapy safety profiles, the need for real-time process monitoring, and the growing complexity of personalized therapies that require sophisticated data analysis.

The market spans multiple technology segments, including machine learning platforms for target identification, AI-driven manufacturing and quality control systems, and digital tools for clinical trial design and patient selection. Geographically, North America and Europe dominate the market due to strong biopharma infrastructure, favorable regulatory frameworks, and concentrated R&D spending, while Asia-Pacific is emerging as a fast-growing region driven by expanding clinical trial activity and government support for advanced therapies. The gene therapy platform segment alone is projected to grow at a 15.2% CAGR through 2030, reflecting broad-based adoption of AI-enabled technologies across different therapeutic modalities.

What are the recent trends and outlook?

The convergence of AI, automation, and advanced manufacturing technologies is expected to continue reshaping cell and gene therapy development, with a long-term projection of the broader gene therapy market reaching between $49 billion and $118 billion by 2035. Key trends include the adoption of digital twins for bioprocess modeling, real-time AI-driven quality assurance, and machine learning-powered patient stratification to improve clinical trial success rates. As AI tools mature and regulatory agencies develop frameworks for their validation, adoption is expected to accelerate across global biopharma ecosystems.